Estuary Biotherapeutics Launches With $103 Million To Develop Gene Therapies For Kidney Disease
Estuary Biotherapeutics has launched with $103 million in committed financing to develop genetic medicines targeting serious kidney diseases, beginning with autosomal dominant polycystic kidney disease....
